SCHEMBL3976375

SCHEMBL3976375

Clc1ccc2c(Cl)nc(-c3ccc(-c4ccccc4)cc3)nc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.54
NPC1 O15118 1/20 0.54
MAPK1 P28482 1/20 0.54
RAB9A P51151 1/20 0.54
AURKA O14965 1/20 0.50
ESR1 P03372 1/20 0.50
ESR2 Q92731 1/20 0.50
DHODH Q02127 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PDE5A O76074 4/20 0.46
ABCG2 Q9UNQ0 2/20 0.46
GBA1 P04062 1/20 0.44
ADORA1 P30542 1/20 0.44
CYP1A2 P05177 1/20 0.44
LMNA P02545 1/20 0.44
NR1I3 Q14994 1/20 0.43
ATM Q13315 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CASP3 P42574 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30439291 0.97 HTT (0.56) HTTNPC1MAPK1RAB9AAURKA
SCHEMBL402767 0.97 HTT (0.56) HTTNPC1MAPK1RAB9AAURKA
SCHEMBL2154965 0.90 NPC1 (0.46) HTTNPC1MAPK1RAB9AAURKA
SCHEMBL3575071 0.85 MAPK1 (0.67) HTTNPC1MAPK1RAB9AMEN1
SCHEMBL17275213 0.84 METAP1 (0.57) HTTNPC1RAB9AMEN1KMT2A
SCHEMBL3976371 0.84 ESR1 (0.48) HTTNPC1MAPK1RAB9AAURKA
SCHEMBL3973373 0.84 CYP1A1 (0.42) HTTNPC1MAPK1RAB9AAURKA
SCHEMBL4847197 0.83 ATM (0.59) HTTNPC1MAPK1RAB9AMEN1
SCHEMBL29593068 0.83 ATM (0.59) HTTNPC1MAPK1RAB9AMEN1
SCHEMBL25463096 0.81 MEN1 (0.57) HTTNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 HTT 3181/4885NPC1 151/4885MAPK1 3502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.